6,565 Shares in Enanta Pharmaceuticals Inc (ENTA) Acquired by Shell Asset Management Co.

Shell Asset Management Co. bought a new position in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,565 shares of the biotechnology company’s stock, valued at approximately $561,000.

Other institutional investors also recently bought and sold shares of the company. Smith Asset Management Group LP acquired a new stake in Enanta Pharmaceuticals during the third quarter worth about $173,000. Victory Capital Management Inc. acquired a new stake in Enanta Pharmaceuticals during the third quarter worth about $245,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Enanta Pharmaceuticals during the third quarter worth approximately $311,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Enanta Pharmaceuticals by 22.6% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 3,747 shares of the biotechnology company’s stock worth $320,000 after purchasing an additional 690 shares in the last quarter. Finally, Yorktown Management & Research Co Inc purchased a new position in Enanta Pharmaceuticals during the second quarter worth approximately $602,000. 85.18% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have issued reports on ENTA. BidaskClub downgraded Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. TheStreet downgraded Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, November 26th. Finally, Oppenheimer set a $100.00 price target on Enanta Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, August 14th. Six investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $104.00.

In other news, VP Nathalie Adda sold 4,155 shares of the firm’s stock in a transaction that occurred on Thursday, September 20th. The stock was sold at an average price of $95.32, for a total value of $396,054.60. Following the transaction, the vice president now owns 4,155 shares in the company, valued at $396,054.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tim Ocain sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $83.64, for a total value of $2,091,000.00. The disclosure for this sale can be found here. Corporate insiders own 10.56% of the company’s stock.

Shares of ENTA stock opened at $73.03 on Friday. The company has a market cap of $1.45 billion, a price-to-earnings ratio of 20.99 and a beta of 0.91. Enanta Pharmaceuticals Inc has a 12-month low of $47.49 and a 12-month high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, November 26th. The biotechnology company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.06. The company had revenue of $67.20 million for the quarter, compared to the consensus estimate of $69.03 million. Enanta Pharmaceuticals had a return on equity of 21.56% and a net margin of 34.82%. Enanta Pharmaceuticals’s revenue for the quarter was down 11.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.86 earnings per share. As a group, equities analysts forecast that Enanta Pharmaceuticals Inc will post 1.7 EPS for the current fiscal year.

WARNING: “6,565 Shares in Enanta Pharmaceuticals Inc (ENTA) Acquired by Shell Asset Management Co.” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/12/08/6565-shares-in-enanta-pharmaceuticals-inc-enta-acquired-by-shell-asset-management-co.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Featured Story: Liquidity

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply